RAVICTI (glycerol phenylbutyrate)

Ravicti (glycerol phenylbutyrate) is a nitrogen-binding agent used for chronic management of patients with urea cycle disorders (UCDs) for whom dietary protein restriction and/or amino acid supplementation is inadequate. This therapeutic drug is used in conjunction with dietary protein restriction and, in certain instances, dietary supplements.

Limitations of Use:
Ravicti is not indicated for the treatment of acute hyperammonemia in patients with urea cycle disorders (UCDs). Additionally, its safety and efficacy for the treatment of N-acetylglutamate synthase (NAGS) deficiency have not been established.

Recommended Dosage: The recommended dose of Ravicti (glycerol phenylbutyrate) oral liquid is taken as prescribed by your healthcare provider (HCP), and they may adjust the dose if needed. Always take it with food or formula, and if breastfeeding an infant, give it just before feeding. Use a new reclosable bottle cap adapter with every new bottle and a new dry oral syringe for each dose to ensure proper administration.

Take any missed dose as soon as it is recognised. However, if the next scheduled dose is within 2 hours for adults and within 30 minutes for children, the missed dose should be omitted, and the usual dosing schedule resumed. Do not double the dose to make up for a missed dose.

• Elevated plasma ammonia due to inadequate dose or therapy noncompliance may lead to neurotoxicity, causing confusion, lethargy, headache, vomiting, or coma. Regular monitoring of ammonia levels is essential to prevent severe neurological impairment and potential long-term cognitive damage.
• Patients with pancreatic insufficiency, such as cystic fibrosis or intestinal malabsorption disorders, may experience reduced drug efficacy because of impaired hydrolysis of glycerol phenylbutyrate. Close monitoring of ammonia levels and alternative therapies should be done in these individuals to maintain metabolic stability.
• Glycerol Phenylbutyrate 1.1 g/mL oral liquid is contraindicated in patients with known hypersensitivity to this drug or its components. Serious allergic reactions, including anaphylaxis, may occur. Stop immediately if hypersensitivity reactions develop, and seek emergency medical care if respiratory distress or severe hypotension is observed.
• Concomitant use of corticosteroids, valproic acid, and haloperidol may elevate ammonia levels, reducing Ravicti's effectiveness. Regular monitoring of plasma ammonia and necessary dose adjustments should be performed when these medications are prescribed alongside Glycerol Phenylbutyrate oral liquid for metabolic stability.
• Glycerol Phenylbutyrate use during pregnancy should be approached with caution, as its safety has not been well established. Potential fetal risks must be weighed against maternal benefits, and pregnant patients should be closely monitored for ammonia control and adverse fetal outcomes.
• The presence of Glycerol Phenylbutyrate or its metabolites in human milk is unknown. Due to potential adverse effects on the nursing infant, a risk-benefit assessment should guide the decision to continue breastfeeding or discontinue Glycerol Phenylbutyrate therapy while lactating.

What documents are required to import RAVICTI to India?

RAVICTI (glycerol phenylbutyrate) oral liquid can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How is the order to be confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit, if applicable

Is RAVICTI available in India?

RAVICTI (glycerol phenylbutyrate oral liquid) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On the availability of Ravicti in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

RAVICTI can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of RAVICTI (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ravicti 1.1 g/mL price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source RAVICTI (Cancer Treatment Medicines) from across the globe and can supply them. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient's address only from New Delhi, India.

What is the Generic Name for the trade name drug Ravicti®?

Glycerol phenylbutyrate is a Generic Name for the trade name drug Ravicti®.

What is the Manufacturer's Name of Ravicti®?

Ravicti® is manufactured by Hyperion Therapeutics.

Is Ravicti approved by the FDA?

Yes, Ravicti® is approved by the FDA. Date of first approval: February 1, 2013.

What is the dosage and form of Ravicti® supplied?

Ravicti is supplied in oral liquid: 1.1 g/mL for oral administration.

What are the most common side effects of Ravicti® 1.1 g/mL oral liquid?

The most common side effects of Ravicti® 1.1 g/mL oral liquid are diarrhea, flatulence, and headache.

How much does Ravicti® 1.1 g/mL oral liquid cost in India?

The prices of Ravicti 1.1 g/mL oral liquid may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Ravicti 1.1 g/mL cost in India, please call/WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

Can Ravicti® 1.1 g/mL oral liquid be available in SAARC countries?

Apart from Gulf countries, Ravicti® can be available in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Ravicti® oral liquid in these countries. We help ensure legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Ravicti® 1.1 g/mL oral liquid online in India?

Yes, one can buy Ravicti 1.1 g/mL online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the legal supply of Ravicti® oral liquid through legal channels.

What are the storage conditions of Ravicti® 1.1 g/mL oral liquid?

Store the 25 mL bottle of oral liquid at 20 to 25°C (68 to 77°F) with excursions permitted to 15 to 30°C (5 to -86°F). Discard the bottle 28 days after opening.